The 3rd CBIC Cell Bio-Industry Conference and Biomedicine Conference

[Pharmaceutical Network Conference Forum] The biopharmaceutical industry is one of the key strategic emerging industries in China.
At present, China is in an important stage of strategic transformation from "generic drugs" to "innovative drugs"
.

Precision medicine promotes the revolution of drug research and development, genetic technology and cell engineering bring revolutionary changes to disease treatment, medical devices begin to become intelligent and standardized, and provide new methods of diagnosis and treatment, contract research and development (CRO), contract manufacturing (CMO), third-party Emerging biomedical service formats such as testing and health management continue to emerge and expand, and the biomedical industry is showing a rapid growth trend
.

In recent years, the national and local governments have successively issued a series of policies to promote the construction of bio-economy, among which the Bohai Rim is headed by Beijing, Tianjin, Hebei and Shandong, the Yangtze River Delta has Shanghai as the core, Jiangsu and Zhejiang are the two wings, and the Pearl River Delta is led by Guangzhou and Shandong.
Shenzhen is the leader, and the three major regional biomedical key areas are clearly clustered, gaining development advantages in industrial competition
.

In this context, the 2022 3rd CBIC Cell Bio-Industry Conference (Subdivision Forum: 2022 Biomedical Innovation Cooperation Conference, 3rd Cell Therapy and Regenerative Medicine Conference) will be held in Shenzhen on March 23-24, 2022.

.

The conference set up two venues, "Biomedical Innovation Cooperation" and "Cell Therapy and Regenerative Medicine", to discuss "New Vaccine Development and Application, New Antibody Drug Opening and Target Screening, Gene Therapy and Oncolytic Virus, Cell Therapy" There are more than 60 presentations in 6 thematic topics including innovation and application, 3D cell culture and clinical application of organoids, cellular exosome regeneration and tumor immune technology research and development.
The discussion angles include technological innovation, clinical research, new policies and regulations, process industrialization, etc.
At that time, it is expected to attract more than 2,000 experts and leaders in the field of biomedicine, including industry, academia, research, and medicine
.

At the same time, relevant theme exhibitions will be held to showcase new products, technologies and services in the industry.
The conference will integrate national biomedical resources and build a one-stop "academic exchange", "channel docking", "market expansion" and "brand promotion" for participants.
platform, enabling the industry to achieve leapfrog development
.

 　　We sincerely invite you to gather in Pengcheng in March for a grand event! 01.
Details of the conference 1.
Conference structure 1) Organization unit: Shenzhen Biomedical Promotion Association, Shenzhen Cell Therapy Technology Association, Shenzhen Life Science Industry Association, Shenzhen Life Science and Biotechnology Association, Guangzhou Instrument Industry Association, China Medical Rescue Association Rescue Resource Guarantee Branch, Shanghai Indoor and Environmental Purification Industry Association, Shanghai Cancer Rehabilitation Club, Shanghai Laboratory Equipment Association, Shanghai Biomedical Industry Association, Shanghai Biomedical Technology Development Center, Wuhan Donghu National Independent Innovation Demonstration Zone Biotechnology Pharmaceutical Industry Association, Guangzhou Zhenghe Exhibition Service Co.
, Ltd.
and other units 2) Time and location March 23-24, 2022, Crowne Plaza Shenzhen Good Days 3) Conference Agenda Topic 1: Innovation and Application of Cell Therapy - Targeting Malignant Solid Tumors Research and development of new technology of immune cell therapy and its application in clinical tumor treatment Xia Jianchuan, Chief Physician of Sun Yat-Sen University Cancer Center—The value of CAR-T innovation reflects Huang Hai, CEO of Fosun Kite—International progress of cell therapy in tumor therapy— Pending Yu Baofa, Chairman of Shandong Baofa Oncology Co.
, Ltd.
- BCMA-targeted CAR-T R&D and clinical progress President of (Shenzhen) Group Co.
, Ltd.
—Research and Development of NK cell functionalAssay Liu Tao, Deputy Director of the Department of Oncology and Immunology of Shenzhen Luohu Hospital Group - The Role of Isolator System and Cell Culture System in Class A Environment in Aseptic Cell Production Process Chen Chao, General Manager of Wenzhou Veken Biological Experiment Equipment Co.
, Ltd.
- New CAR - Research and development of T cells and mechanism research Li Peng, Researcher of Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences - Application of Stem Cells in Cardiovascular Precision Medicine Zhang Zhe, Distinguished Researcher of Shenzhen Bay Laboratory - Internet of Things Smart Cell Preparation Full-Scenario Solution Innovative Application Yu Hongdong, Director of Haier Biological Culture Scenario - Nanobody Technology and Gene Editing Technology "Assisting" CAR-T Cell Therapy Xu Guangxian, Second-level Professor of Guangdong Medical University, Deputy Director of Guangdong Provincial Key Laboratory of Medical Molecular Diagnosis Topic 2: 3D Cell Culture Clinical Application of Organoids—Incoming Omicron, How Organoids Can Help New Coronavirus Research Li Gang, Chief Physician of Nanfang Hospital, Southern Medical University—Cultivation of Tumor Organoids and Its Application in Precision Medicine Applications and Challenges of Organoids in Animal Nutrition and Disease Research Zhou Jian, Ph.
D.
, Institute of Subtropical Agroecology, Chinese Academy of Sciences - Organoid and Stem Cell Engineering , Senior Technical Officer of Organoids, Guangzhou Jingke Life Sciences Research Institute—Tumor Organoid Related Translational Research Yao Ye, Resident/Clinical Postdoctoral Fellow at Sun Yat-sen University Cancer Center—to be determined Cai Jian, Deputy Director of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University Physician Charting Table Meeting:1.
In terms of preoperative neoadjuvant therapy, postoperative chemotherapy, maintenance therapy, and recurrence therapy, how should organoid technology intervene to help clinicians and solve clinical problems? 2.
In the process of clinical application of organoid drug sensitivity, How to ensure that the process is compliant and legal? 3.
What guiding significance can organoid technology bring to the clinic in the selection of the initial treatment plan? 4.
In the process of drug use, can the organoid drug susceptibility result become a clinical reference index? Topic 3: Cellular exosome regeneration and tumor immune technology research and development - exosomes and the treatment of central nervous system diseases Cheng Fang, Associate Professor of Sun Yat-Sen University—Large-scale Preparation of Exosomes and Its Application in the Treatment of Immune Diseases Application in Characterization Wu Shengfu, Technical Support - Single Exosome High-throughput Identification Technology and Liquid Biopsy, Xiamen Fuliu Biotechnology Co.
, Ltd.
Cai Yanling, Chief Scientific Officer of Shenzhen Mima Technology Co.
, Ltd.
- Research and Development of Neoantigen-Based Tumor Immunity Technology Dong Xuan, Associate Researcher of Shenzhen BGI Research Institute of Life Sciences, Head of Cell Engineering Center of Super Cell Research Institute - Research Progress of Stem Cell Therapy for Male Sexual Dysfunction and Intervention—The Impact of Adipose-derived Stem Cells on the Future of Medical Aesthetics and the Big Health IndustryJia, Professor and Doctoral Supervisor of the School of Basic Medicine, Jinan University, Director of Guangdong Small Nucleic Acid Drug Development Engineering Technology Research Center - Machine Learning Algorithms Accelerates the R&D Process of mRNA Delivery System Ouyang Defang, Institute of Chinese Medicine, University of Macau - Bispecific Mechanism Innovation in Antibody Development Wu Chenbing, Founder and President of Shanganmai Biotechnology Co.
, Ltd.
—to be determined Zhang Zhan, Chairman of Shenzhen Weiguang Biological Products Co.
, Ltd.
—siRNA drug development—Design and consideration of adenovirus as a vaccine carrier— Development and application of mRNA new crown vaccine - application of organoid platform in mRNA drug development and transformation - measles and mumps Chinese vaccine strain reverse genetic system and its application in new crown recombinant vector vaccine candidate Topic 2: New antibody drug development and Target Screening - In-depth Characterization of ADC Drugs Based on Agilent Analysis Platform Chen Xi, Agilent Technologies Principle Application Scientist - Application of Organoid and New Drug Development Marketing and User Operations Wang Wentao, Vice President of Xiaoetong, Head of Zhongtai Product Center - Innovative Targeted Drug Research and Development of AI+ Disease Model Zhang Haisheng, Founder and CEO of Xigshengke (Shenzhen) Co.
, Ltd.
- China Cardiac Safety and Cardiotoxicity The latest progress in detection technology Li Li, Medical Director of Beijing Merrill Lynch Technology Co.
, Ltd.
—Pharmacokinetic Research & Clinical Research of Biotechnology Drugs Zhong Guoping, Director of the Institute of Clinical Pharmacology, Sun Yat-Sen University—to be determined, China Medical Rescue Association Rescue Resource Guarantee Branch Topic 3: Gene Therapy and Oncolytic Viruses - To be determined Maohua, Partner, Director and General Manager of Frost & Sullivan Greater China - To be determined Peng Jiao, Shenzhen Yuanxing Gene Technology Co.
, Ltd.
- Oncolytic virus clinical research progress and Looking forward to Ni Dongyao, Chief R&D Officer of Shenzhen Inuowei Pharmaceutical Technology Co.
, Ltd.
—Progress in Clinical Research on Oncolytic Type II Herpes Simplex Virus and Introduction of Related Pipelines Solutions Yalin Liu, Deputy Director of AAV Product Strategy, WuXi Gene Therapy Drug Release Criteria:Gene Editing Off-target Detection and Verification Tian Rui, CTO of Zhuhai Shutong Medical Technology Co.
, Ltd.
- Global status and development trend of oncolytic virus industry - Adeno-associated virus vector tumor gene therapy - AVV-mediated nerve regeneration gene therapy 4) Conference registration VIP Exclusive ticket: 1280 yuan/person, original price 1980 yuan, the original price will be restored on March 7th: 1.
One general conference ticket; 2.
Two-day lunch on March 23-24; One document; 5.
One exclusive commemorative gift; VIP exclusive group ticket (4 people): 3840 yuan Benefits: 1.
Four general conference tickets; 2.
Four lunches on March 23-24; 3.
Conference site Four exclusive seats; 4.
Four copies of conference materials; 5.
Four copies of exclusive commemorative gifts;